If you only read headlines about Novavax slashing COVID-era sales and leaning on partners like Sanofi and Pfizer, the share result over the next year might surprise you. Holding Novavax over the past year would have returned 22.3%, including dividends. If you had been weighing up a position back in November 2025 with analysts split between shrinking revenues and rich P/E assumptions, what exactly in the record could have justified taking that risk?
Novavax is not the only name tied to this theme. Zero in on 37 healthcare AI stocks and compare how each one is priced.
The shares cost US$7.06 at the start of the period, so anyone looking at Novavax then had to decide which story felt more realistic.
On the upbeat side, one narrative saw a licensing led future where partnerships and a leaner structure supported new royalty streams. That view implied a Fair Value of US$12.5, a rough estimate of what the stock might trade at if revenue fell 31.4% a year and profit margin settled at 16.0%.
The more cautious view focused on a narrow vaccine portfolio and heavier regulatory pressure. In that scenario, the Fair Value was set at US$6, based on assumptions of revenue declining 54.0% a year and the business needing a 72.6x future P/E to justify that outcome.
Novavax’s later reports showed the pivot that the upbeat case was banking on, with Pfizer and Sanofi licensing deals delivering upfront payments. Q3 2026 still recorded a loss of US$31.4 million, however, even as net margin improved to -45.9% from -287.3%. That mix supported the optimistic partnership story but left the profitability assumption unproven.
The lesson here is clear. When a thesis leans on a licensing shift, you track two things in filings: the share of revenue from partners, and whether the net margin actually turns positive.
Novavax now trades at US$8.53, with the cautious analyst Narrative on Simply Wall St setting a Fair Value below that market level based on its own assumptions. The stock has gained 22.3% over the past year, so the question shifts from survival to what that higher entry price expects.
The Narrative leans on Matrix M licensing as the hinge. A buyer today effectively needs recurring royalties and milestones to build fast enough to support the current valuation, and must weigh that against the risk that partner delays or weaker program progress hold those cash flows back.
"The current valuation implies the share price already reflects successful execution on Matrix M driven royalty growth, Sanofi related milestones through 2029, and a durable position in a large combination vaccine category despite recent revenue declines and leadership criticism."
One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all
The story behind this run has already been told. The next one could be taking shape somewhere else. Where could you start looking before it becomes the headline?
That is three of the list. See every one of the 35 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com